Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2

Fig. 1

Kaplan–Meier curves for progression-free survival (PFS) (A) and time-to-progression (TTP) in the MetNET2 study cohort (B). Box plots depicting changes in the indicated metabolic parameters during the experimental treatment (C–H). The p value in panels C–H refers to the paired t test for the indicated comparisons

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us